Positive Outlook for MDxHealth: Strategic Moves and Undervalued Growth Potential Reinforce Buy Rating
I'm PortAI, I can summarize articles.
William Blair analyst Andrew Brackmann has reiterated a Buy rating on MDxHealth (MDXH) due to a positive outlook despite a slight miss in Q3 revenue expectations. The company maintained profitability and reduced cash usage, focusing on integrating ExoDx while delaying germline testing. Strong revenue guidance and undervalued stock potential support long-term growth. TD Cowen also maintains a Buy rating with a $7.00 price target, reflecting confidence in MDxHealth's future opportunities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments